Certara (NASDAQ:CERT) Hits New 1-Year Low – What’s Next?

Certara, Inc. (NASDAQ:CERT)’s stock price hit a new 52-week low on Monday . The company traded as low as $6.02 and last traded at $6.1750, with a volume of 857447 shares. The stock had previously closed at $6.15.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on CERT. Barclays reissued an “equal weight” rating and set a $8.00 price objective on shares of Certara in a report on Friday, March 6th. Stephens reduced their target price on Certara from $15.00 to $12.00 and set an “overweight” rating for the company in a report on Friday, December 12th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. KeyCorp lowered their price target on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a report on Thursday, January 8th. Finally, Morgan Stanley dropped their price target on shares of Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Certara currently has a consensus rating of “Hold” and an average target price of $11.10.

Certara Stock Down 1.6%

The company has a debt-to-equity ratio of 0.27, a current ratio of 2.05 and a quick ratio of 2.05. The firm has a market capitalization of $994.63 million, a P/E ratio of -625.00 and a beta of 1.50. The business has a 50 day moving average price of $7.56 and a 200 day moving average price of $9.39.

Certara (NASDAQ:CERT) last announced its earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The business had revenue of $103.65 million for the quarter, compared to the consensus estimate of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. Certara’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, analysts predict that Certara, Inc. will post 0.28 earnings per share for the current year.

Institutional Investors Weigh In On Certara

Hedge funds have recently modified their holdings of the business. Tejara Capital Ltd boosted its holdings in Certara by 94.9% in the 3rd quarter. Tejara Capital Ltd now owns 273,052 shares of the company’s stock valued at $3,337,000 after purchasing an additional 132,927 shares during the period. Sector Gamma AS acquired a new stake in Certara in the 3rd quarter worth $2,818,000. Kopion Asset Management LLC increased its holdings in shares of Certara by 49.9% during the 4th quarter. Kopion Asset Management LLC now owns 982,710 shares of the company’s stock worth $8,658,000 after purchasing an additional 327,064 shares during the period. Fort Washington Investment Advisors Inc. OH bought a new position in shares of Certara during the 3rd quarter worth about $11,899,000. Finally, Dixon Mitchell Investment Counsel Inc. acquired a new position in shares of Certara during the third quarter valued at about $10,587,000. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.